Predicted Impacts:
Projected Drug Spending

State legislatures will continue to battle high drug prices and tire of inaction from the federal government. The number of states enacting laws that target high drug prices, such as price transparency and rebates will increase.

Without federal legislation on lowering drug pricing, such as speeding up drug approvals, making generic drugs far cheaper for Medicare beneficiaries, and making changes to trade policy, companies will increasingly be forced to meet different state requirements instead of only one from the federal government.

Understanding nonadherence in patients and encouraging a change in attitude toward patients and their medication will improve medication adherence.

As more patents for name-brand prescriptions expire, the use of generics will continue to increase. However, the lack of available generics for specialty drugs will keep prices for those prescriptions high.

Predicted Impacts:
Medicare Part D Prescription Drug Coverage

Proposed changes in the President’s FY2019 Budget will result in fewer Medicare Part D enrollees reaching the catastrophic coverage phase in future years since they would be required to spend more out-of-pocket to pass through the coverage gap and enter the catastrophic phase of the benefit.

Medicare Part D beneficiaries will receive discounts on specialty drugs, including biosimilars and preferred drugs.
Predicted Impacts:
Public Opinion on Drug Costs & Proposed Controls

A growing number of states will push legislation to launch their own plans to import drugs. These moves will spur pharmaceutical and life sciences companies to consider new ways to justify pricing, manage legal and regulatory uncertainty, and consider novel cross-sector collaborations to show value.